Front Row Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Front Row Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.32K	Hold	7	–	–	﹤0.01%	493
2025 Q4	$2.78K	Hold	7	–	–	﹤0.01%	476
2025 Q3	$3.19K	Sell	7 -2	-22%	-$814	﹤0.01%	468
2025 Q2	$2.94K	Sell	9 -5	-36%	-$1.38K	﹤0.01%	456
2025 Q1	$3.78K	Hold	14	–	–	﹤0.01%	426
2024 Q4	$3.29K	Hold	14	–	–	﹤0.01%	426
2024 Q3	$3.85K	Hold	14	–	–	﹤0.01%	421
2024 Q2	$3.4K	Hold	14	–	–	﹤0.01%	794
2024 Q1	$2.09K	Hold	14	–	–	﹤0.01%	843
2023 Q4	$2.68K	Hold	14	–	–	﹤0.01%	403
2023 Q3	$2.48K	Hold	14	–	–	﹤0.01%	788
2023 Q2	$3K	Hold	14	–	–	﹤0.01%	743
2023 Q1	$3K	Buy	+14	New	+$2.94K	﹤0.01%	751
2022 Q4	–	Sell	-14	Closed	-$3K	–	881
2022 Q3	$3K	Hold	14	–	–	﹤0.01%	735
2022 Q2	$2K	Hold	14	–	–	﹤0.01%	796
2022 Q1	$2K	Hold	14	–	–	﹤0.01%	838
2021 Q4	$2K	Hold	14	–	–	﹤0.01%	863
2021 Q3	$3K	Hold	14	–	–	﹤0.01%	804
2021 Q2	$3K	Hold	14	–	–	﹤0.01%	806
2021 Q1	$2K	Hold	14	–	–	﹤0.01%	850
2020 Q4	$2K	Hold	14	–	–	﹤0.01%	812
2020 Q3	$2K	Hold	14	–	–	﹤0.01%	810
2020 Q2	$2K	Hold	14	–	–	﹤0.01%	814
2020 Q1	$2K	Hold	14	–	–	﹤0.01%	790
2019 Q4	$2K	Hold	14	–	–	﹤0.01%	766
2019 Q3	$1K	Hold	14	–	–	﹤0.01%	844
2019 Q2	$1K	Hold	14	–	–	﹤0.01%	921
2019 Q1	$1K	Buy	+14	New	+$1.17K	﹤0.01%	921

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Front Row Advisors's ALNY Position: Q1 2026 in Review

Front Row Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 7 shares worth $2.32K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

Front Row Advisors first reported a position in ALNY in Q1 2019 and has held it in 28 quarters since. The position peaked at $3.85K in Q3 2024. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Front Row Advisors held 7 shares of Alnylam Pharmaceuticals worth $2.32K as of Q1 2026.
Front Row Advisors left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #493 holding.
Front Row Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
Front Row Advisors's Alnylam Pharmaceuticals position peaked at $3.85K in Q3 2024.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.